{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T17:59:30Z","timestamp":1776103170250,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006447","name":"Universit\u00e4t Z\u00fcrich","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["New Microbes and New Infections"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.nmni.2026.101734","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T16:28:37Z","timestamp":1772209717000},"page":"101734","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Amikacin exposure in MDR-TB patients in Uganda: Revisiting old drugs in a new era of resistance \u2013 A pharmacokinetic assessment"],"prefix":"10.1016","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0844-4231","authenticated-orcid":false,"given":"Jan","family":"Hongler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Haller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akello Susan","family":"Adakun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan","family":"Buzibye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marisa","family":"K\u00e4lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Castelnuovo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Sekaggya-Wiltshire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Abongomera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Jetter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Fehr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmni.2026.101734_bib1","series-title":"Global tuberculosis report 2025","year":"2025"},{"issue":"10","key":"10.1016\/j.nmni.2026.101734_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0259221","article-title":"Rifampicin and isoniazid drug resistance among patients diagnosed with pulmonary tuberculosis in southwestern Uganda","volume":"16","author":"Micheni","year":"2021","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.nmni.2026.101734_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070763","article-title":"Anti-tuberculosis drug resistance among new and previously treated sputum smear-positive tuberculosis patients in Uganda: results of the first national survey","volume":"8","author":"Lukoye","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.nmni.2026.101734_bib4","series-title":"Quality of tuberculosis services assessment in Uganda","author":"Oyediran","year":"2020"},{"key":"10.1016\/j.nmni.2026.101734_bib5","series-title":"Consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment","year":"2020"},{"issue":"9","key":"10.1016\/j.nmni.2026.101734_bib6","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline\u2013pretomanid\u2013linezolid regimens for drug-resistant Tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"New England J Med"},{"issue":"4","key":"10.1016\/j.nmni.2026.101734_bib7","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/S2666-5247(20)30031-8","article-title":"Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis","volume":"1","author":"Nimmo","year":"2020","journal-title":"Lancet Microbe"},{"issue":"1","key":"10.1016\/j.nmni.2026.101734_bib8","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1186\/s12879-025-11067-2","article-title":"Prevalence of bedaquiline resistance in patients with drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"25","author":"Hu","year":"2025","journal-title":"BMC Infect Dis"},{"issue":"3","key":"10.1016\/j.nmni.2026.101734_bib9","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1473-3099(23)00498-X","article-title":"Emergence of bedaquiline-resistant tuberculosis and of multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis strains with rpoB Ile491Phe mutation not detected by Xpert MTB\/RIF in Mozambique: a retrospective observational study","volume":"24","author":"Barilar","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.nmni.2026.101734_bib10","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01275-23","article-title":"Sub-MIC levels of bedaquiline and clofazimine can select Mycobacterium tuberculosis mutants with increased MIC","volume":"68","author":"Villellas","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"issue":"22","key":"10.1016\/j.nmni.2026.101734_bib11","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1056\/NEJMc1815121","article-title":"Bedaquiline microheteroresistance after cessation of tuberculosis treatment","volume":"380","author":"de Vos","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmni.2026.101734_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(25)00218-X","article-title":"Treatment outcomes of bedaquiline-resistant tuberculosis: a retrospective and matched cohort study","author":"Mdlenyani","year":"2025","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.nmni.2026.101734_bib13","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1473-3099(21)00470-9","article-title":"Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study","volume":"22","author":"Ismail","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"10.1016\/j.nmni.2026.101734_bib14","first-page":"622","article-title":"Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis","volume":"6","author":"de Jager","year":"2002","journal-title":"Int J Tubercul Lung Dis"},{"key":"10.1016\/j.nmni.2026.101734_bib15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1472-6815-7-5","article-title":"Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-up","volume":"7","author":"Duggal","year":"2007","journal-title":"BMC Ear Nose Throat Disord"},{"issue":"10","key":"10.1016\/j.nmni.2026.101734_bib16","doi-asserted-by":"crossref","first-page":"6337","DOI":"10.1128\/AAC.01050-15","article-title":"Amikacin concentrations predictive of ototoxicity in multidrug-resistant tuberculosis patients","volume":"59","author":"Modongo","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.nmni.2026.101734_bib17","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1186\/1471-2334-14-542","article-title":"Successful MDR-TB treatment regimens including amikacin are associated with high rates of hearing loss","volume":"14","author":"Modongo","year":"2014","journal-title":"BMC Infect Dis"},{"issue":"suppl_3","key":"10.1016\/j.nmni.2026.101734_bib18","doi-asserted-by":"crossref","first-page":"S303","DOI":"10.1093\/cid\/ciy613","article-title":"Amikacin dosing for MDR tuberculosis: a systematic review to establish or revise the current recommended dose for tuberculosis treatment","volume":"67","author":"Sturkenboom","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.nmni.2026.101734_bib19","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01400-16","article-title":"Reduced chance of hearing loss associated with therapeutic drug monitoring of aminoglycosides in the treatment of multidrug-resistant tuberculosis","volume":"61","author":"van Altena","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.nmni.2026.101734_bib20","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/0196-0709(89)90002-1","article-title":"Incidence of amikacin ototoxicity: a sigmoid function of total drug exposure independent of plasma levels","volume":"10","author":"Beaubien","year":"1989","journal-title":"Am J Otolaryngol"},{"key":"10.1016\/j.nmni.2026.101734_bib21","article-title":"Role of therapeutic drug monitoring in the treatment of multi-drug resistant tuberculosis","volume":"36","author":"Maranchick","year":"2024","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"issue":"3","key":"10.1016\/j.nmni.2026.101734_bib22","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ijantimicag.2015.06.008","article-title":"Limited sampling strategies for therapeutic drug monitoring of amikacin and kanamycin in patients with multidrug-resistant tuberculosis","volume":"46","author":"Dijkstra","year":"2015","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"10.1016\/j.nmni.2026.101734_bib23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1177\/0310057X1404200210","article-title":"Limited sampling strategy for estimation of amikacin optimal sampling time in critically ill adults","volume":"42","author":"Mahmoudi","year":"2014","journal-title":"Anaesth Intensive Care"},{"key":"10.1016\/j.nmni.2026.101734_bib24","series-title":"Addendum to the national guidelines for the programmatic management of drug-resistant tuberculosis","year":"2019"},{"key":"10.1016\/j.nmni.2026.101734_bib25","series-title":"Uganda national guidelines for the programmatic management of drug-resistant tuberculosis","year":"2016"},{"issue":"19","key":"10.1016\/j.nmni.2026.101734_bib26","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New Creatinine- and cystatin C-Based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.nmni.2026.101734_bib27","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s12879-021-05947-6","article-title":"Low-dose amikacin in the treatment of Multidrug-resistant tuberculosis (MDR-TB)","volume":"21","author":"Sabur","year":"2021","journal-title":"BMC Infect Dis"},{"issue":"2","key":"10.1016\/j.nmni.2026.101734_bib28","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40262-016-0428-x","article-title":"Amikacin in critically ill patients: a review of population pharmacokinetic studies","volume":"56","author":"Marsot","year":"2017","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.nmni.2026.101734_bib29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40262-012-0020-y","article-title":"Benchmarking therapeutic drug monitoring software: a review of available computer tools","volume":"52","author":"Fuchs","year":"2013","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.nmni.2026.101734_bib30","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0924-8579(00)00172-2","article-title":"Population pharmacokinetics of tobramycin in hospitalized patients receiving once-daily dosing regimen","volume":"15","author":"Xuan","year":"2000","journal-title":"Int J Antimicrob Agents"}],"container-title":["New Microbes and New Infections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2052297526000387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2052297526000387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T16:55:51Z","timestamp":1776099351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2052297526000387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":30,"alternative-id":["S2052297526000387"],"URL":"https:\/\/doi.org\/10.1016\/j.nmni.2026.101734","relation":{},"ISSN":["2052-2975"],"issn-type":[{"value":"2052-2975","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amikacin exposure in MDR-TB patients in Uganda: Revisiting old drugs in a new era of resistance \u2013 A pharmacokinetic assessment","name":"articletitle","label":"Article Title"},{"value":"New Microbes and New Infections","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmni.2026.101734","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101734"}}